anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, real-world data
DISEASE INTERVENTION COMPARISON RESULTS
Circulation. 2018 Feb 28. doi: 10.1161/CIRCULATIONAHA.117.031658. [Epub ahead of print] Cohorts
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, real-world data, very elderly patients The Use of
these 3 direct oral anticoagulants
As Treatment, Chronic
Is better Than
warfarin
To reduce the risk of intracranial bleeding (0.42 %/year DOAs VS 1.63 % warfarin) with similar effect in stroke and all-type major bleeding.
Stroke. 2017 09;48(9):2494-2503 Cohorts
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, real-world data The Use of
these direct oral anticoagulants
As Treatment, Chronic
Is better Than
warfarin
To reduce mortality (for dabigatran and apixaban (HR 0.65 both)), achieve similar rate of ischemic stroke or embolism, reduce intracranial bleeding (all 3 drugs, HR 0.40 to 0.65) but increasing gastrointestinal bleeding (except apixaban)